Pediatric Clinical Trials
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: VTX-2337 plus radiotherapy
Eligibility
Major Inclusion Criteria:
- low grade B cell lymphoma
- 1 or more sites of disease appropriate for intratumoral injection
- measurable disease other than the injection site
- Performance Status of 1 or better
- Adequate bone marrow, renal and hepatic function
- No active autoimmune disease or systemic immunosuppressive drugs
- Life expectancy > 4 months
Exclusion Criteria:
- Known HIV
- Known brain metastases
- Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)
- Anticoagulation therapy other than 325mg QD ASA
- Significant cardiovascular disease
- Pregnant or nursing
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Lori Richards
6507258589
Not Recruiting